Liver International

© John Wiley & Sons A/S

Cover image for Vol. 32 Issue s1

Special Issue: Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C

February 2012

Volume 32, Issue Supplement s1

Pages 1–156

  1. Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C

    1. Top of page
    2. Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C
    3. Review Articles

    1. The publication of this supplement was supported by an unrestricted educational grant from Roche (founding partner), Merck and Janssen

      Editorial
      You have free access to this content
      Towards the eradication of hepatitis C virus (page 1)

      Patrick Marcellin and Tarik Asselah

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02726.x

  2. Review Articles

    1. Top of page
    2. Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C
    3. Review Articles
    1. You have free access to this content
      2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines (pages 2–8)

      Vincenza Calvaruso and Antonio Craxì

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02703.x

    2. You have free access to this content
      New targets for antiviral therapy of chronic hepatitis C (pages 9–16)

      Sandra Bühler and Ralf Bartenschlager

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02701.x

    3. You have free access to this content
      Telaprevir user's guide (pages 17–25)

      Ann Marie Liapakis and Ira Jacobson

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02708.x

    4. You have free access to this content
      Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1 (pages 27–31)

      Michael P. Manns, Antoaneta A. Markova, Beatriz Calle Serrano and Markus Cornberg

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02725.x

    5. You have free access to this content
      Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice (pages 32–38)

      Christophe Hézode

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02707.x

    6. You have free access to this content
      Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin (pages 39–43)

      Paul Y. Kwo

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02709.x

    7. You have free access to this content
      Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders (pages 44–50)

      Nicole Forestier and Stefan Zeuzem

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02720.x

    8. You have free access to this content
      Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders (pages 51–53)

      Bruce R. Bacon and Omer Khalid

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02700.x

    9. You have free access to this content
      Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? (pages 54–60)

      Mitchell L. Shiffman and Rafael Esteban

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02718.x

    10. You have free access to this content
      Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: ‘Lead-in or no lead-in’? (pages 61–63)

      Graham R. Foster and Lawrence D. Serfaty

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02717.x

    11. You have free access to this content
      Response-guided and -unguided treatment of chronic hepatitis C (pages 64–73)

      K. Rajender Reddy, Frederick Lin and Fabien Zoulim

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02713.x

    12. You have free access to this content
      IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? (pages 74–78)

      Donald M. Jensen and Stanislas Pol

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02712.x

    13. You have free access to this content
      Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? (pages 79–87)

      Philippe Halfon and Christoph Sarrazin

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02716.x

    14. You have free access to this content
      Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow (pages 88–102)

      Tarik Asselah and Patrick Marcellin

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02699.x

    15. You have free access to this content
      The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C (pages 103–107)

      Virginia Clark and David R. Nelson

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02711.x

    16. You have free access to this content
      Treatment of chronic hepatitis C – are interferons really necessary? (pages 108–112)

      Peter Ferenci

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02705.x

    17. You have free access to this content
      Future treatment of patients with HCV cirrhosis (pages 113–119)

      Marc Bourlière, Asma Khaloun, Claire Wartelle-Bladou, Valérie Oules, Isabelle Portal, Souad Benali, Xavier Adhoute and Paul Castellani

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02702.x

    18. You have free access to this content
      Hepatitis C virus treatment pre- and post-liver transplantation (pages 120–128)

      Bruno Roche and Didier Samuel

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02714.x

    19. You have free access to this content
      Hepatitis C virus-human immunodeficiency virus coinfection (pages 129–134)

      Mark S. Sulkowski

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02719.x

    20. You have free access to this content
      What's new in HCV genotype 2 treatment (pages 135–140)

      Alessandra Mangia and Leonardo Mottola

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02710.x

    21. You have free access to this content
      Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies (pages 141–145)

      Shiv K. Sarin and Chandan K. N. Kumar

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02715.x

    22. You have free access to this content
      The future for the treatment of genotype 4 chronic hepatitis C (pages 146–150)

      G. Esmat, M. El Raziky, M. El Kassas, M. Hassany and M.E. Gamil

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02704.x

    23. You have free access to this content
      Barriers to hepatitis C treatment (pages 151–156)

      Christopher E. McGowan and Michael W. Fried

      Article first published online: 29 DEC 2011 | DOI: 10.1111/j.1478-3231.2011.02706.x

SEARCH

SEARCH BY CITATION